Eledon Pharmaceuticals Inc (ELDN) - News Archive

Eledon Pharmaceuticals: Navigating the Terrain of Kidney Transplant Research and Revenue ChallengesEledon Pharmaceuticals Inc., a biopharmaceutical company focusing on therapeutics for kidney transplant recipients, is c...

In a significant development within the biotechnology sector, Eledon Pharmaceuticals has made notable strides in its mission to enhance organ transplant outcomes. The company recently announced the successful completion...

Eledon Pharmaceuticals, a pioneering biotechnology company focused on advancing therapies for patients requiring organ transplants, has recently announced the successful completion of enrollment for its Phase 2 BESTOW c...

Eledon Pharmaceuticals Inc. has recently provided an enrollment update for its Phase 2 BESTOW trial, assessing the efficacy of tegoprubart in preventing organ rejection among transplant patients. As the biotech landscap...

Eledon Unveils Promising Data from Phase 1b Trial of Tegoprubart for Kidney Transplant Rejection Prevention Eledon Pharmaceuticals, a trailblazing biotech firm dedicated to innovative immunotherapeutic solutions, recent...

As major contributors in the field of clinical science and biopharmaceutical research, Eledon Pharmaceuticals continues to make considerable strides in the development of groundbreaking medications. At the forefront of...

Eledon Pharmaceuticals, a leading biopharmaceutical company focused on the development of novel therapies with transformative potential, is making noteworthy strides in the field of organ transplantation. Recently, the...

Organ transplants have the potential to save countless lives, yet the risk of organ rejection continues to pose a significant challenge in post-transplant care. In an exciting development, Eledon Pharmaceuticals recentl...

Eledon Pharmaceuticals Inc., since its inception, has consistently dedicated to leverage scientific discovery and drug development to address the world’s most pressing health-care challenges remarkably. The agenda is no...